BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol. 2017;28:583-589. [PMID: 27998967 DOI: 10.1093/annonc/mdw640] [Cited by in Crossref: 372] [Cited by in F6Publishing: 395] [Article Influence: 62.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Y, Chen H, Tang L, Feng Y, Tao Y, Huang L, Lou N, Shi Y. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Immunotherapy 2023. [PMID: 36710655 DOI: 10.2217/imt-2022-0028] [Reference Citation Analysis]
2 Jiang N, Yu Y, Wu D, Wang S, Fang Y, Miao H, Ma P, Huang H, Zhang M, Zhang Y, Tang Y, Li N. HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events. J Cancer Res Clin Oncol 2023. [PMID: 36662304 DOI: 10.1007/s00432-022-04493-1] [Reference Citation Analysis]
3 Chen ZH, Zheng WH, Wu CF, Kou J, Yang XL, Lin L, Lv JW, Sun Y, Zhou GQ. Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. BMC Med 2023;21:18. [PMID: 36647058 DOI: 10.1186/s12916-022-02697-3] [Reference Citation Analysis]
4 Taylor J, Gandhi A, Gray E, Zaenker P. Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. Front Immunol 2022;13:991433. [PMID: 36713389 DOI: 10.3389/fimmu.2022.991433] [Reference Citation Analysis]
5 Xing X, Zhao Q, Zhou J, Zhou R, Liu Y, Qin X, Zhang M, Zhong Y, Wang J, Tian M, Zhang H. Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. Eur J Nucl Med Mol Imaging 2023. [PMID: 36622406 DOI: 10.1007/s00259-022-06084-1] [Reference Citation Analysis]
6 Shalit A, Sarantis P, Koustas E, Trifylli EM, Matthaios D, Karamouzis MV. Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers (Basel) 2023;15. [PMID: 36672324 DOI: 10.3390/cancers15020375] [Reference Citation Analysis]
7 Lee SM, Lee S, Cho HW, Min KJ, Hong JH, Song JY, Lee JK, Lee NW. Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors? Int J Mol Sci 2023;24. [PMID: 36674491 DOI: 10.3390/ijms24020974] [Reference Citation Analysis]
8 Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. J Immunother Cancer 2023;11. [PMID: 36593068 DOI: 10.1136/jitc-2022-005493] [Reference Citation Analysis]
9 Renz M, Dorigo O. Immunotherapy in gynecologic malignancies. DiSaia and Creasman Clinical Gynecologic Oncology 2023. [DOI: 10.1016/b978-0-323-77684-4.00026-x] [Reference Citation Analysis]
10 Elshot YS, Blok SG, Bekkenk MW, Matos TR. Dermatologic autoimmunity associated with immune checkpoint inhibitors. Translational Autoimmunity 2023. [DOI: 10.1016/b978-0-323-85389-7.00015-6] [Reference Citation Analysis]
11 Zhao J, Li D, Xie S, Deng X, Wen X, Li J, Wu Z, Yang X, Li M, Tang Y, Zhang X, Ding Y. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis. Front Immunol 2022;13:1083840. [PMID: 36618343 DOI: 10.3389/fimmu.2022.1083840] [Reference Citation Analysis]
12 Pani F, Yasuda Y, Rousseau ST, Bermea KC, Roshanmehr S, Wang R, Yegnasubramanian S, Caturegli P, Adamo L. Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors. J Immunother Cancer 2022;10. [PMID: 36521928 DOI: 10.1136/jitc-2022-005538] [Reference Citation Analysis]
13 Marie MA, McCallen JD, Hamedi ZS, Naqash AR, Hoffman A, Atwell D, Amara S, Muzaffar M, Walker PR, Yang LV. Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review. Front Oncol 2022;12:1023545. [PMID: 36568170 DOI: 10.3389/fonc.2022.1023545] [Reference Citation Analysis]
14 Zhang Y, Li J, Yang F, Zhang X, Ren X, Wei F. Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer. J Leukoc Biol 2022;112:1591-603. [PMID: 35501298 DOI: 10.1002/JLB.5MA0322-746R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hara Y, Baba Y, Toihata T, Harada K, Ogawa K, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Baba H. Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab. J Gastrointest Oncol 2022;13:2779-88. [PMID: 36636073 DOI: 10.21037/jgo-22-281] [Reference Citation Analysis]
16 Hayashi H, Sawada K, Hasebe T, Nakajima S, Sawada J, Takiyama Y, Takiyama Y, Okumura T, Fujiya M. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events. Intern Med 2022;61:3497-502. [PMID: 35491133 DOI: 10.2169/internalmedicine.9393-22] [Reference Citation Analysis]
17 de Filette JMK, André S, De Mey L, Aspeslagh S, Karmali R, Van der Auwera BJ, Bravenboer B. Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms. BMC Endocr Disord 2022;22:291. [PMID: 36419114 DOI: 10.1186/s12902-022-01190-5] [Reference Citation Analysis]
18 Wu L, Xu Y, Wang X, Cheng X, Zhang Y, Wang Y, Fan X, Zhao H, Liu H, Chai X, Zhang L, Wang M, Li N, Pan H, Lian X. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.. [DOI: 10.21203/rs.3.rs-2210602/v1] [Reference Citation Analysis]
19 Thyroid Gland. Non-Neoplastic Disorders of the Endocrine System 2022. [DOI: 10.55418/9781933477251-3] [Reference Citation Analysis]
20 Zander T, Hallek M. Was muss der Internist bei Patienten unter Biologikabehandlung beachten? rheuma plus 2022;21:268-273. [DOI: 10.1007/s12688-022-00536-0] [Reference Citation Analysis]
21 Gritsch D, Valencia-sanchez C. Drug-related immune-mediated myelopathies. Front Neurol 2022;13:1003270. [DOI: 10.3389/fneur.2022.1003270] [Reference Citation Analysis]
22 Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol 2022;13:1010279. [DOI: 10.3389/fendo.2022.1010279] [Reference Citation Analysis]
23 Mari R, Guerin M, Vicier C, Walz J, Bonnet N, Pignot G, Gravis G. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. Front Immunol 2022;13:984132. [DOI: 10.3389/fimmu.2022.984132] [Reference Citation Analysis]
24 Califaretti E, Dall’armellina S, Rovera G, Finessi M, Deandreis D. The role of PET/CT in thyroid autoimmune diseases. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03464-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Seguí E, Zamora-martínez C, Barreto TD, Padrosa J, Viladot M, Marco-hernández J. Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. Diagnostics 2022;12:2116. [DOI: 10.3390/diagnostics12092116] [Reference Citation Analysis]
26 Fang J, Yu L, Zhuang L, Pei X, Wang Q, Jin G. The changes in peripheral blood Th17 and Treg ratios in Hashimoto’s thyroiditis are accompanied by differential PD-1/PD-L1 expression. Front Endocrinol 2022;13:959477. [DOI: 10.3389/fendo.2022.959477] [Reference Citation Analysis]
27 Tian BW, Han CL, Dong ZR, Tan SY, Wang DX, Li T. Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4036. [PMID: 36011030 DOI: 10.3390/cancers14164036] [Reference Citation Analysis]
28 Burnett DL, Barnet MB, Samaras K. Editorial: Decoding checkpoint inhibitor-induced endocrinopathies. Front Endocrinol 2022;13:987648. [DOI: 10.3389/fendo.2022.987648] [Reference Citation Analysis]
29 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
30 Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS. J Endocrinol Invest. [DOI: 10.1007/s40618-022-01845-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Glibka AA, Mazurina NV, Sarantseva KA, Kharkevich GY, Laktionov KK, Troshina EA, Mel`nichenko GA. Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors. Almanac of Clinical Medicine 2022. [DOI: 10.18786/2072-0505-2022-50-020] [Reference Citation Analysis]
32 Liao Z, Kong Y, Zeng L, Wan Q, Hu J, Cai Y. Effects of high-fat diet on thyroid autoimmunity in the female rat. BMC Endocr Disord 2022;22:179. [PMID: 35840950 DOI: 10.1186/s12902-022-01093-5] [Reference Citation Analysis]
33 Chye A, Allen I, Barnet M, Burnett DL. Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. Front Oncol 2022;12:894015. [DOI: 10.3389/fonc.2022.894015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Issa M, Tang J, Guo Y, Coss C, Mace TA, Bischof J, Phelps M, Presley CJ, Owen DH. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. Expert Rev Anticancer Ther 2022;:1-14. [PMID: 35786142 DOI: 10.1080/14737140.2022.2094772] [Reference Citation Analysis]
35 Armstrong S, Roy T, Singh B, Kulasekaran M, Shaukat F, Geng X, Wang H, Prins P, Jha RC, Hartley ML, He AR. TKIs beyond immunotherapy predict improved survival in advanced HCC. J Cancer Res Clin Oncol 2022. [PMID: 35773429 DOI: 10.1007/s00432-022-04115-w] [Reference Citation Analysis]
36 Deligiorgi MV, Trafalis DT. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists. Expert Rev Clin Pharmacol 2022. [PMID: 35757870 DOI: 10.1080/17512433.2022.2093714] [Reference Citation Analysis]
37 Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Les I, Pérez-Francisco I, Cabero M, Sánchez C, Hidalgo M, Teijeira L, Arrazubi V, Domínguez S, Anaut P, Eguiluz S, Elejalde I, Herrera A, Martínez M. Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. Front Pharmacol 2022;13:894550. [PMID: 35721217 DOI: 10.3389/fphar.2022.894550] [Reference Citation Analysis]
39 Labadzhyan A, Wentzel K, Hamid O, Chow K, Kim S, Piro L, Melmed S. Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study. J Clin Endocrinol Metab 2022;107:1976-82. [PMID: 35303106 DOI: 10.1210/clinem/dgac161] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Deligiorgi MV, Trafalis DT. The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum. J Clin Med 2022;11:3417. [PMID: 35743483 DOI: 10.3390/jcm11123417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Rahman MM, Behl T, Islam MR, Alam MN, Islam MM, Albarrati A, Albratty M, Meraya AM, Bungau SG. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules 2022;27:3798. [PMID: 35744922 DOI: 10.3390/molecules27123798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
42 Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax 2022:thoraxjnl-2020-215614. [PMID: 35688624 DOI: 10.1136/thoraxjnl-2020-215614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-illescas D, Pardo N, Navarro A, Martinez-marti A, Cedres S, Carbonell C, Frigola J, Amat R, Felip E. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med 2022;9:875974. [DOI: 10.3389/fmed.2022.875974] [Reference Citation Analysis]
44 Chieng JHL, Htet ZW, Zhao JJ, Tai ES, Tay SH, Huang Y, Wong A, Yang SP. Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers 2022;14:2687. [DOI: 10.3390/cancers14112687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zhou X, Chen X, Han L, Liu H. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. Clin Sci (Lond) 2022;136:771-85. [PMID: 35621125 DOI: 10.1042/CS20210042] [Reference Citation Analysis]
46 Zhuang J, Chen Z, Chen Z, Chen J, Liu M, Xu X, Liu Y, Yang S, Hu Z, He F. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma. Respir Res 2022;23:123. [PMID: 35562727 DOI: 10.1186/s12931-022-02043-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Kotwal A, Mcleod DS. Thyroid Dysfunction from Treatments for Solid Organ Cancers. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Fattizzo B, Rampi N, Barcellini W. Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. Pharmaceuticals 2022;15:557. [DOI: 10.3390/ph15050557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Gastaldi M, Scaranzin S, Pietro B, Lechiara A, Pesce G, Franciotta D, Lorusso L. Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New. Curr Oncol Rep 2022. [PMID: 35476177 DOI: 10.1007/s11912-022-01279-z] [Reference Citation Analysis]
50 Yamada H, Washino S, Suzuki D, Saikawa R, Tonezawa S, Hagiwara R, Funazaki S, Yoshida M, Konishi T, Saito K, Miyagawa T, Hara K. Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma. BMC Endocr Disord 2022;22:110. [PMID: 35468815 DOI: 10.1186/s12902-022-01024-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Trudu L, Guaitoli G, Bertolini F, Maur M, Santini C, Papapietro VR, Talerico S, Natalizio S, Isca C, Dominici M, Barbieri F. Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report. Immunotherapy 2022. [PMID: 35416048 DOI: 10.2217/imt-2021-0165] [Reference Citation Analysis]
52 Ye Z, Zheng S, Chen J, Zhang Y, Yang S, Hong Y, Yang H, Xuan Z, Zhao Q. Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients? Int Immunopharmacol 2022;108:108738. [PMID: 35395468 DOI: 10.1016/j.intimp.2022.108738] [Reference Citation Analysis]
53 Baek HS, Jeong C, Shin K, Lee J, Suh H, Lim DJ, Kang MI, Ha J. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. BMC Endocr Disord 2022;22:89. [PMID: 35379219 DOI: 10.1186/s12902-022-01004-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Castel-ajgal Z, Goulvestre C, Zaibet S, Arrondeau J, Bretagne M, Peyromaure M, Batteux F, Alexandre J, Goldwasser F, Huillard O. Pre-existing autoantibodies and immune related adverse events in metastatic urothelial carcinoma patients treated by pembrolizumab. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.04.002] [Reference Citation Analysis]
55 Patti L, Musso L, Ferone D, Albertelli M. Inibitori dei checkpoint immunitari e patologia tiroidea. L'Endocrinologo 2022;23:125-132. [DOI: 10.1007/s40619-022-01038-z] [Reference Citation Analysis]
56 Jessel S, Weiss SA, Austin M, Mahajan A, Etts K, Zhang L, Aizenbud L, Perdigoto AL, Hurwitz M, Sznol M, Herold KC, Kluger HM. Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Front Oncol 2022;12:836859. [PMID: 35350573 DOI: 10.3389/fonc.2022.836859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
57 Paschou SA, Liontos M, Eleftherakis-papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos M. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Front Oncol 2022;12:847917. [DOI: 10.3389/fonc.2022.847917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ueno T, Yamashita M, Yamashita N, Uomoto M, Kawamata O, Sano Y, Inokawa H, Hirayama S, Okazaki M, Toyooka S. Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg 2022. [PMID: 35304712 DOI: 10.1007/s11748-022-01798-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhang K, Kong X, Li Y, Wang Z, Zhang L, Xuan L. PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. Front Pharmacol 2022;13:854967. [DOI: 10.3389/fphar.2022.854967] [Reference Citation Analysis]
60 Adda L, Batteux B, Saidak Z, Poulet C, Arnault J, Chauffert B, Séjourné A. Effets indésirables rhumatologiques associés aux inhibiteurs de points de contrôle immunitaire : impact sur la survie globale. Revue du Rhumatisme 2022;89:168-175. [DOI: 10.1016/j.rhum.2021.10.564] [Reference Citation Analysis]
61 Dawidowska A, Jagodzinska-Mucha P, Koseła-Paterczyk H, Jaczewska S, Sobczuk P, Chelstowska M, Kowalska M, Badziak-Sterczewska H, Poleszczuk J, Rutkowski P, Lugowska I. Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. Cancers (Basel) 2022;14:1248. [PMID: 35267557 DOI: 10.3390/cancers14051248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Mosaferi T, Tsai K, Sovich S, Wilhalme H, Kathuria-Prakash N, Praw SS, Drakaki A, Angell TE, Lechner MG. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis. Thyroid 2022;32:496-504. [PMID: 35199588 DOI: 10.1089/thy.2021.0685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S. Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. Cells 2022;11:770. [PMID: 35269392 DOI: 10.3390/cells11050770] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
64 Barnabei A, Corsello A, Paragliola RM, Iannantuono GM, Falzone L, Corsello SM, Torino F. Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle. Cancers (Basel) 2022;14:1057. [PMID: 35205804 DOI: 10.3390/cancers14041057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 George AS, Fernandez CJ, Eapen D, Pappachan JM. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. touchREV Endocrinol 2021;17:21-32. [PMID: 35118443 DOI: 10.17925/EE.2021.17.1.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Wang Y, Zhou P, Cui C, He X, Bian Y, Wang X. The expression of Nanog protein and fibroblast growth factor-inducible molecule 14 in patients with non-small cell lung cancer and their relationship with pathological characteristics and prognosis. Transl Cancer Res 2021;10:2470-7. [PMID: 35116561 DOI: 10.21037/tcr-21-724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Mcgregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews 2022;103:102333. [DOI: 10.1016/j.ctrv.2021.102333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
68 Ghosh N, Postow M, Zhu C, Jannat-khah D, Li Q, Vitone G, Chan KK, Bass AR. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. J Immunother Cancer 2022;10:e004008. [DOI: 10.1136/jitc-2021-004008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
69 Kida W, Nakaya M, Ito A, Kozai Y, Bingo M. A Case of Acquired Factor V Inhibitor Following Nivolumab Administration. Cureus 2022. [DOI: 10.7759/cureus.21670] [Reference Citation Analysis]
70 Michielin O, Lalani A, Robert C, Sharma P, Peters S. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. J Immunother Cancer 2022;10:e003024. [DOI: 10.1136/jitc-2021-003024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
71 von Itzstein MS, Gonugunta AS, Wang Y, Sheffield T, Lu R, Ali S, Fattah FJ, Xie D, Cai J, Xie Y, Gerber DE. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2022. [PMID: 35072744 DOI: 10.1007/s00262-022-03151-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Pratumchart N, Chanprapaph K, Topibulpong N, Tankunakorn J. Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review. Clin Cosmet Investig Dermatol 2022;15:51-62. [PMID: 35046689 DOI: 10.2147/CCID.S344445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Delire B, De Martin E, Meunier L, Larrey D, Horsmans Y. Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. Front Pharmacol 2022;12:786174. [DOI: 10.3389/fphar.2021.786174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Duong SL, Prüss H. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. Neurotherapeutics 2022. [PMID: 35043373 DOI: 10.1007/s13311-022-01184-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Skribek M, Rounis K, Tsakonas G, Ekman S. Complications following novel therapies for non-small cell lung cancer. J Intern Med 2022. [PMID: 35032058 DOI: 10.1111/joim.13445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Cheung YM, Wang W, McGregor B, Hamnvik OR. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 2022. [PMID: 35022907 DOI: 10.1007/s00262-021-03128-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
77 Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat 2022. [PMID: 35015209 DOI: 10.1007/s10549-021-06480-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
78 Guo H, Qian L, Chen X, Zhao Y, Song W, Guan Y, Cui J. A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice. Open Med (Wars) 2022;17:53-60. [PMID: 34993345 DOI: 10.1515/med-2021-0404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Cómbita Rojas AL. Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy. Revista Colombiana de Reumatología (English Edition) 2022;29:1-2. [DOI: 10.1016/j.rcreue.2022.01.001] [Reference Citation Analysis]
80 Girotra M. Endocrinopathies Associated With Immune Checkpoint Inhibitors. Endocrine Emergencies 2022. [DOI: 10.1016/b978-0-323-76097-3.00024-7] [Reference Citation Analysis]
81 Cómbita Rojas AL. Autoanticuerpos: una manifestación de los eventos adversos inmunológicos de la inmunoterapia en cáncer. Revista Colombiana de Reumatología 2022;29:1-2. [DOI: 10.1016/j.rcreu.2021.11.001] [Reference Citation Analysis]
82 Balavoine A. Maladies générales, médicaments et fonction thyroïdienne. Les Maladies de la Thyroïde 2022. [DOI: 10.1016/b978-2-294-77583-3.00022-8] [Reference Citation Analysis]
83 Chen Y, Li Y. Metabolic reprogramming and immunity in cancer. Cancer Immunology and Immunotherapy 2022. [DOI: 10.1016/b978-0-12-823397-9.00006-5] [Reference Citation Analysis]
84 Fujii K, Imai T, Miyakura Y, Hasegawa K, Nakazato A, Morita S, Saijyo S, Asada Y. A case of pembrolizumab-induced hypopituitarism subsequent to hypothyroidism. Toukeibu Gan 2022;48:295-300. [DOI: 10.5981/jjhnc.48.295] [Reference Citation Analysis]
85 Varghese J, Best C. Endocrine. Managing Immunotherapy Related Organ Toxicities 2022. [DOI: 10.1007/978-3-031-00241-0_4] [Reference Citation Analysis]
86 Deligiorgi MV, Trafalis DT. The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research. Int J Mol Sci 2021;23:436. [PMID: 35008863 DOI: 10.3390/ijms23010436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Kotwal A, Rouleau SG, Dasari S, Kottschade L, Ryder M, Kudva YC, Markovic S, Erickson D. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort. J Investig Med 2021:jim-2021-002099. [PMID: 34969937 DOI: 10.1136/jim-2021-002099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Chen R, Peng L, Qiu Z, Wang Y, Wei F, Zhou M, Zhu F. Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors. Front Cardiovasc Med 2021;8:727445. [PMID: 34938778 DOI: 10.3389/fcvm.2021.727445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Kotwal A, Cheung YM, Cromwell G, Drincic A, Leblebjian H, Quandt Z, Rushakoff RJ, McDonnell ME. Patient-Centered Diabetes Care of Cancer Patients. Curr Diab Rep 2021;21:62. [PMID: 34902069 DOI: 10.1007/s11892-021-01435-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
90 da Silva JA, Falcão D, Cardoso C, Pires AL, Araújo A, Castro-Poças F. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience. Ann Hepatol 2021;26:100561. [PMID: 34653687 DOI: 10.1016/j.aohep.2021.100561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Zhang Q, Wang W, Yuan Q, Li L, Wang YC, Chi CZ, Xu CH. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol 2021. [PMID: 34821962 DOI: 10.1007/s00280-021-04375-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
92 Bardoscia L, Pasinetti N, Triggiani L, Cozzi S, Sardaro A. Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. Front Pharmacol 2021;12:746853. [PMID: 34790123 DOI: 10.3389/fphar.2021.746853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
93 Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Kodera Y, Arima H. Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J Clin Endocrinol Metab 2021:dgab829. [PMID: 34791304 DOI: 10.1210/clinem/dgab829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
94 Fidilio E, Navarro-González E, Romero-Lluch AR, Iglesias P, Diez Gómez JJ, Anda Apiñániz E, Santos Mazo E, Zafón C. Thyroid disorders associated with immune control point inhibitors. Endocrinol Diabetes Nutr (Engl Ed) 2021;68:408-15. [PMID: 34742474 DOI: 10.1016/j.endien.2021.10.004] [Reference Citation Analysis]
95 Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Sci Immunol 2021;6:eabf4034. [PMID: 34739340 DOI: 10.1126/sciimmunol.abf4034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M, Xu Y, Zhao J, Zhong W, Wang M. Risk factors for immune-related adverse events: what have we learned and what lies ahead? Biomark Res 2021;9:79. [PMID: 34732257 DOI: 10.1186/s40364-021-00314-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
97 Percik R, Liel Y, Urban D, Bar J, Ben-Ami E, Abu Tailakh M. Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database. Acta Oncol 2021;60:1466-71. [PMID: 34379562 DOI: 10.1080/0284186X.2021.1958006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Katakura Y, Kimura T, Kusano T, Tatsumi F, Iwamoto Y, Sanada J, Fushimi Y, Shimoda M, Kohara K, Nakanishi S, Kaku K, Mune T, Kaneto H. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency. Front Endocrinol (Lausanne) 2021;12:722586. [PMID: 34712202 DOI: 10.3389/fendo.2021.722586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Deligiorgi MV, Sagredou S, Vakkas L, Trafalis DT. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries. Cancers (Basel) 2021;13:5277. [PMID: 34771441 DOI: 10.3390/cancers13215277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
100 Zhao Z, Wang X, Qu J, Zuo W, Tang Y, Zhu H, Chen X. Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:708195. [PMID: 34604047 DOI: 10.3389/fonc.2021.708195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
101 Chmielewska I, Dudzińska M, Szczyrek M, Świrska J, Wojas-Krawczyk K, Zwolak A. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab? PLoS One 2021;16:e0257484. [PMID: 34587185 DOI: 10.1371/journal.pone.0257484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Hwang S, Kim H, Chung S, Min M, Suh D. Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors. Korean J Clin Pharm 2021;31:188-197. [DOI: 10.24304/kjcp.2021.31.3.188] [Reference Citation Analysis]
103 Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer 2020;8:e000779. [PMID: 32606047 DOI: 10.1136/jitc-2020-000779] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
104 Kubo T, Hirohashi Y, Tsukahara T, Kanaseki T, Murata K, Morita R, Torigoe T. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. Immunol Med 2021;:1-11. [PMID: 34542015 DOI: 10.1080/25785826.2021.1976942] [Reference Citation Analysis]
105 Xu L, Leng C, Chen L, Dong H, Chen Y, Chen X. Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma. Int J Cancer 2021. [PMID: 34536292 DOI: 10.1002/ijc.33813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Sibille A, Henket M, Corhay JL, Alfieri R, Louis R, Duysinx B. White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung 2021;199:549-57. [PMID: 34518898 DOI: 10.1007/s00408-021-00474-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
107 Hagiwara R, Suzuki D, Tonezawa S, Saikawa R, Funazaki S, Yoshida M, Washino S, Miyagawa T, Hara K, Yamada H. Spontaneous recovery of immune checkpoint inhibitor-induced thyroiditis with high free T4 level: A case report. Clin Case Rep 2021;9:e04781. [PMID: 34512984 DOI: 10.1002/ccr3.4781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, Yessuf NM, Rettinger S, Grogan T, Rochigneux P, Goldman JW, Garon EB, Lisberg A. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer 2021;161:34-41. [PMID: 34507111 DOI: 10.1016/j.lungcan.2021.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Giommoni E, Giorgione R, Paderi A, Pellegrini E, Gambale E, Marini A, Antonuzzo A, Marconcini R, Roviello G, Matucci-cerinic M, Capaccioli D, Pillozzi S, Antonuzzo L. Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. Immuno 2021;1:253-63. [DOI: 10.3390/immuno1030017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
110 Lyadova MA, Lyadov VK. Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. J Mod Onco 2021;23:319-326. [DOI: 10.26442/18151434.2021.2.200502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 [PMID: 34457186 DOI: 10.4251/wjgo.v13.i8.772] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
112 Oğuz SH, Ünlütürk U, Aksoy S, Erbas T. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review. Immunotherapy 2021. [PMID: 34387129 DOI: 10.2217/imt-2021-0061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
113 Matsui N, Kouda K, Ishihara N, Tamaki H, Yano T, Naora K, Kitahara T. Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. Jpn J Pharm Health Care Sci 2021;47:437-444. [DOI: 10.5649/jjphcs.47.437] [Reference Citation Analysis]
114 Walters AGB, Braatvedt G. Endocrine adverse effects of immune checkpoint inhibitors. Intern Med J 2021;51:1016-20. [PMID: 34278695 DOI: 10.1111/imj.14992] [Reference Citation Analysis]
115 Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 2021. [PMID: 34316029 DOI: 10.1038/s41573-021-00259-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
116 Kotwal A, Ryder M. Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers. Curr Opin Endocrinol Diabetes Obes 2021;28:517-24. [PMID: 34269714 DOI: 10.1097/MED.0000000000000664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
117 Yasuda Y, Iwama S, Sugiyama D, Okuji T, Kobayashi T, Ito M, Okada N, Enomoto A, Ito S, Yan Y, Sugiyama M, Onoue T, Tsunekawa T, Ito Y, Takagi H, Hagiwara D, Goto M, Suga H, Banno R, Takahashi M, Nishikawa H, Arima H. CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med 2021;13:eabb7495. [PMID: 33980577 DOI: 10.1126/scitranslmed.abb7495] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
118 Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:263. [PMID: 34248142 DOI: 10.1038/s41392-021-00658-5] [Cited by in Crossref: 164] [Cited by in F6Publishing: 193] [Article Influence: 82.0] [Reference Citation Analysis]
119 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 45.5] [Reference Citation Analysis]
120 Desharnais L, Walsh LA, Quail DF. Exploiting the obesity-associated immune microenvironment for cancer therapeutics. Pharmacol Ther 2021;:107923. [PMID: 34171329 DOI: 10.1016/j.pharmthera.2021.107923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Li S, Sharma N, Kazmierski D, Amjad MA, Dong Y, Wang Y, Sharma N, Ramakrishna S, Ochieng P. Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy. Cureus 2021;13:e15805. [PMID: 34306873 DOI: 10.7759/cureus.15805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, Saito S, Narumi A, Ogasawara T, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. Cancer Med 2021;10:4796-804. [PMID: 34121358 DOI: 10.1002/cam4.4045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
123 Zhan L, Feng HF, Liu HQ, Guo LT, Chen C, Yao XL, Sun SR. Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. Front Endocrinol (Lausanne) 2021;12:649863. [PMID: 34177799 DOI: 10.3389/fendo.2021.649863] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
124 Kotwal A. Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management. Curr Opin Endocrinol Diabetes Obes 2021;28:427-34. [PMID: 34183541 DOI: 10.1097/MED.0000000000000652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Khan Z, Hammer C, Carroll J, Di Nucci F, Acosta SL, Maiya V, Bhangale T, Hunkapiller J, Mellman I, Albert ML, McCarthy MI, Chandler GS. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat Commun 2021;12:3355. [PMID: 34099659 DOI: 10.1038/s41467-021-23661-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
126 Frelau A, Jali E, Campillo-Gimenez B, Pracht M, Porneuf M, Dinulescu M, Edeline J, Boussemart L, Lesimple T. Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. Melanoma Res 2021;31:208-17. [PMID: 33904517 DOI: 10.1097/CMR.0000000000000739] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
127 Fidilio E, Navarro-gonzález E, Romero-lluch AR, Iglesias P, Diez Gómez JJ, Anda Apiñániz E, Santos Mazo E, Zafón C. Alteraciones tiroideas asociadas con los inhibidores de los puntos de control inmunitario. Endocrinología, Diabetes y Nutrición 2021;68:408-415. [DOI: 10.1016/j.endinu.2020.04.007] [Reference Citation Analysis]
128 Fu Y, Zheng Y, Wang PP, Ding ZY. Toxicities of Immunotherapy for Small Cell Lung Cancer. Front Oncol 2021;11:603658. [PMID: 34136376 DOI: 10.3389/fonc.2021.603658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Li Y, Zhang Y, Jia X, Jiang P, Mao Z, Liang T, Du Y, Zhang J, Zhang G, Niu G, Guo H. Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis. Clin Lung Cancer 2021:S1525-7304(21)00098-X. [PMID: 34183265 DOI: 10.1016/j.cllc.2021.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
130 Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. Endocrine 2021. [PMID: 34036513 DOI: 10.1007/s12020-021-02750-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Zheng X, Wei H. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. Front Oncol 2021;11:628243. [PMID: 34094910 DOI: 10.3389/fonc.2021.628243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Parikh M, Bajwa P. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. Semin Nephrol 2020;40:76-85. [PMID: 32130969 DOI: 10.1016/j.semnephrol.2019.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
133 Iwama S, Kobayashi T, Arima H. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors. Endocrinol Metab (Seoul) 2021;36:312-21. [PMID: 33934588 DOI: 10.3803/EnM.2021.1007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
134 Hata H, Mio T, Yamashita D, Matsumura C, Chisaki Y, Motohashi H, Yano Y. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. Cancer Control 2020;27:1073274820977200. [PMID: 33297768 DOI: 10.1177/1073274820977200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
135 Lu L, Xing K, Wei W, Ling Y, Li P, Li S, Wang Y, Xie D, Guo R, Cai M. Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma. Int J Cancer 2021. [PMID: 33890283 DOI: 10.1002/ijc.33609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
136 Shimozaki K, Sukawa Y, Sato Y, Horie S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Kanai T. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncol 2021;17:2593-603. [PMID: 33878916 DOI: 10.2217/fon-2020-0861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
137 Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 2021:dgab263. [PMID: 33878162 DOI: 10.1210/clinem/dgab263] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
138 Peiffert M, Cugnet-Anceau C, Dalle S, Chikh K, Assaad S, Disse E, Raverot G, Borson-Chazot F, Abeillon-du Payrat J. Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers (Basel) 2021;13:1944. [PMID: 33920721 DOI: 10.3390/cancers13081944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
139 Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, Hao Y, Zhang Z. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Front Oncol 2021;11:633032. [PMID: 33912454 DOI: 10.3389/fonc.2021.633032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
140 Valencia-Sanchez C, Zekeridou A. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy. Front Neurol 2021;12:642800. [PMID: 33897597 DOI: 10.3389/fneur.2021.642800] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
141 Goyal I, Pandey MR, Sharma R, Chaudhuri A, Dandona P. The side effects of immune checkpoint inhibitor therapy on the endocrine system. Indian J Med Res 2021;154:559-70. [PMID: 35435341 DOI: 10.4103/ijmr.IJMR_313_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Li B, Jiang C, Pang L, Zou B, Ding M, Sun X, Yu J, Wang L. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review. Front Immunol 2021;12:627197. [PMID: 33859637 DOI: 10.3389/fimmu.2021.627197] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
143 Iglesias P, Sánchez JC, Díez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary 2021;24:630-43. [PMID: 33761049 DOI: 10.1007/s11102-021-01141-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
144 D'Aiello A, Lin J, Gucalp R, Tabatabaie V, Cheng H, Bloomgarden NA, Tomer Y, Halmos B. Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers (Basel) 2021;13:1464. [PMID: 33806774 DOI: 10.3390/cancers13061464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
145 Dadu R, Rodgers TE, Trinh VA, Kemp EH, Cubb TD, Patel S, Simon JM, Burton EM, Tawbi H. Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. J Immunother Cancer 2020;8:e000687. [PMID: 32581059 DOI: 10.1136/jitc-2020-000687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
146 Chen X, Nie J, Dai L, Hu W, Zhang J, Han J, Ma X, Tian G, Han S, Wu D, Wang Y, Long J, Zhang Z, Fang J. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. Front Oncol 2021;11:607531. [PMID: 33747922 DOI: 10.3389/fonc.2021.607531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
147 Adda L, Batteux B, Saidak Z, Poulet C, Arnault JP, Chauffert B, Séjourné A. Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival. Joint Bone Spine 2021;88:105168. [PMID: 33675979 DOI: 10.1016/j.jbspin.2021.105168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
148 Anderson B, Morganstein DL. Endocrine toxicity of cancer immunotherapy: clinical challenges. Endocr Connect 2021;10:R116-24. [PMID: 33544091 DOI: 10.1530/EC-20-0489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
149 Wang D, Chen C, Gu Y, Lu W, Zhan P, Liu H, Lv T, Song Y, Zhang F. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:631949. [PMID: 33732650 DOI: 10.3389/fonc.2021.631949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
150 Freitas C, Jacob M, Tavares N, Cruz-Martins N, Souto-Moura C, Araújo D, Novais-Bastos H, Santos V, Fernandes G, Magalhães A, Hespanhol V, Queiroga H. Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anticancer Drugs 2021;32:567-74. [PMID: 33661189 DOI: 10.1097/CAD.0000000000001060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Sachpekidis C, Hassel JC, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A. Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. Cancers (Basel) 2021;13:1019. [PMID: 33804417 DOI: 10.3390/cancers13051019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
152 Nashed A, Zhang S, Chiang C, Zitu M, Otterson GA, Presley CJ, Kendra K, Patel SH, Johns A, Li M, Grogan M, Lopez G, Owen DH, Li L. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunol Immunother 2021;70:2761-9. [DOI: 10.1007/s00262-021-02880-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
153 Peravali M, Gomes-Lima C, Tefera E, Baker M, Sherchan M, Farid S, Burman K, Constantinescu F, Veytsman I. Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses. World J Clin Oncol 2021; 12(2): 103-114 [PMID: 33680877 DOI: 10.5306/wjco.v12.i2.103] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
154 Zhong L, Wu Q, Chen F, Liu J, Xie X. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:2559-76. [PMID: 33576872 DOI: 10.1007/s00262-020-02803-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
155 Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. Endocr Pract 2021:S1530-891X(21)00030-6. [PMID: 33581327 DOI: 10.1016/j.eprac.2021.01.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
156 Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review. Front Oncol 2020;10:585311. [PMID: 33643899 DOI: 10.3389/fonc.2020.585311] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
157 Anderson MA, Kurra V, Bradley W, Kilcoyne A, Mojtahed A, Lee SI. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. Br J Radiol 2021;94:20200663. [PMID: 33112648 DOI: 10.1259/bjr.20200663] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
158 Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, Cheung A, Chauhan J, Bax HJ, Chenoweth A, Laddach R, Osborn G, McCraw A, Hoffmann RM, Nakamura M, Geh JL, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Papa S, Barber L, Lacy KE, Karagiannis SN. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Front Immunol 2020;11:622442. [PMID: 33569063 DOI: 10.3389/fimmu.2020.622442] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
159 Yamauchi I, Yasoda A, Hakata T, Yamashita T, Hirota K, Ueda Y, Fujii T, Taura D, Sone M, Inagaki N. Novel Thyroid-Specific Autoantibodies in Patients with Immune-Related Adverse Events Involving the Thyroid Gland.. [DOI: 10.1101/2021.01.14.426670] [Reference Citation Analysis]
160 Thuillier P, Joly C, Alavi Z, Crouzeix G, Descourt R, Quere G, Kerlan V, Roudaut N. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol Immunother 2021;70:2023-33. [PMID: 33423089 DOI: 10.1007/s00262-020-02802-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
161 Paschou SA, Stefanaki K, Psaltopoulou T, Liontos M, Koutsoukos K, Zagouri F, Lambrinoudaki I, Dimopoulos MA. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open 2021;6:100011. [PMID: 33399077 DOI: 10.1016/j.esmoop.2020.100011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
162 Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis. Cancer Treatment Reviews 2021;92:102134. [DOI: 10.1016/j.ctrv.2020.102134] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 38.0] [Reference Citation Analysis]
163 Ksienski D, Wai ES, Alex D, Croteau NS, Freeman AT, Chan A, Patterson T, Clarkson M, Fiorino L, Poonja Z, Fenton D, Irons S, Lesperance M. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. Transl Lung Cancer Res 2021;10:355-67. [PMID: 33569318 DOI: 10.21037/tlcr-20-541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
164 Rengarajan M, Gainor JF. Endocrine immune-related adverse events: a double-edged sword? Transl Lung Cancer Res 2021;10:13-7. [PMID: 33569289 DOI: 10.21037/tlcr-2020-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 George AS, Fernandez CJ, Eapen D, Pappachan JM; Department of Medical Oncology, Lakeshore Hospital, Cochin, Kerala, India, Department of Endocrinology, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston, UK, Department of Endocrinology, Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust, Boston, UK, Department of Endocrinology & Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston, UK, Manchester Metropolitan University, Manchester, UK, The University of Manchester, Manchester, UK. Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. European Endocrinology 2021;1:21. [DOI: 10.17925/ee.2021.1.1.21] [Reference Citation Analysis]
166 Davies M, Russo A. Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. Lung Cancer 2021. [DOI: 10.1007/978-3-030-74028-3_7] [Reference Citation Analysis]
167 Itonaga T, Saito K, Ikeda N, Mikami R. Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors. Acta Radiol 2021;62:42-50. [PMID: 32268773 DOI: 10.1177/0284185120916197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Izzedine H, Chazal T, Wanchoo R, Jhaveri KD. Immune checkpoint inhibitor-associated hypercalcaemia. Nephrol Dial Transplant 2020:gfaa326. [PMID: 33374000 DOI: 10.1093/ndt/gfaa326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
169 Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabrò L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, Castagna MG. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 2021;44:1719-26. [PMID: 33367977 DOI: 10.1007/s40618-020-01480-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
170 Zhou Y, Xia R, Xiao H, Pu D, Long Y, Ding Z, Liu J, Ma X. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. Int Immunopharmacol 2021;91:107296. [PMID: 33360368 DOI: 10.1016/j.intimp.2020.107296] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
171 Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H. Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Rev Neurother 2021;21:205-19. [PMID: 33225764 DOI: 10.1080/14737175.2020.1855144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
172 Conde-estévez D, Monge-escartín I, Ríos-hoyo A, Monzonis X, Echeverría-esnal D, Moliner L, Duran-jordà X, Taus Á, Arriola E. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. Journal of Chemotherapy 2021;33:32-9. [DOI: 10.1080/1120009x.2020.1849488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
173 Dall'Olio FG, Rizzo A, Mollica V, Massucci M, Maggio I, Massari F. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 2021;13:257-70. [PMID: 33225800 DOI: 10.2217/imt-2020-0179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
174 Biniakewitz MD, Kasler MK, Fessele KL. Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. Asia Pac J Oncol Nurs 2021;8:18-24. [PMID: 33426185 DOI: 10.4103/apjon.apjon_48_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Londoño MC, Reig M; RETOINMUNO Multidisciplinary Group. Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. Cancers (Basel) 2020;12:E3446. [PMID: 33228219 DOI: 10.3390/cancers12113446] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
176 Zhao Z, Wang X, Bao XQ, Ning J, Shang M, Zhang D. Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review. Cancer Immunol Immunother 2021;70:1527-40. [PMID: 33200250 DOI: 10.1007/s00262-020-02699-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
177 Cui TM, Liu Y, Wang JB, Liu LX. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11725-40. [PMID: 33235462 DOI: 10.2147/OTT.S279858] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
178 Bade BC, Possick JD. Pulmonary Complications of Immunotherapy. Clin Chest Med 2020;41:295-305. [PMID: 32402364 DOI: 10.1016/j.ccm.2020.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 El Sabbagh R, Azar NS, Eid AA, Azar ST. Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review. Int J Gen Med 2020;13:1003-9. [PMID: 33177863 DOI: 10.2147/IJGM.S261433] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
180 Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, Li C, Cheng B, Xiong S, Li J, He J, Liang W. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials. Cancer 2021;127:777-86. [PMID: 33119182 DOI: 10.1002/cncr.33270] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
181 Paydary K, Zain Farooq M, Mangla A. History of Radiation to the Neck Increases the Risk of Denovo Thyroid Dysfunction after Receiving Immune Checkpoint Inhibitors. Endocrines 2020;1:82-89. [DOI: 10.3390/endocrines1020008] [Reference Citation Analysis]
182 Yamauchi I, Taura D, Hakata T, Fujita H, Okamoto K, Ueda Y, Fujii T, Inagaki N. Clinical features and thyroid dysfunction in adverse events involving the pituitary gland during PD-1 blockade therapy. Clin Endocrinol (Oxf) 2021;94:258-68. [PMID: 33037658 DOI: 10.1111/cen.14349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
183 Yao J, Wang Z, Sheng J, Wang H, You L, Zhu X, Pan H, Han W. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study. Int Immunopharmacol 2020;89:107033. [PMID: 33039958 DOI: 10.1016/j.intimp.2020.107033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
184 Xu Y, Fu Y, Zhu B, Wang J, Zhang B. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Front Immunol 2020;11:2023. [PMID: 33123120 DOI: 10.3389/fimmu.2020.02023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
185 Krishnamurthy A, Bhattacharya S, Lathia T, Kantroo V, Kalra S, Dutta D. Anticancer Medications and Sodium Dysmetabolism. Eur Endocrinol. 2020;16:122-130. [PMID: 33117443 DOI: 10.17925/ee.2020.16.2.122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
186 Silvestris N, Argentiero A, Beretta GD, Di Bartolo P, Montagnani M, Danesi R, Ferrari P, D'Oronzo S, Gori S, Russo A, Acquati S, Gallo M. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2020;154:103066. [PMID: 32853883 DOI: 10.1016/j.critrevonc.2020.103066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
187 Economopoulou P, Kotsantis I, Papaxoinis G, Gavrielatou N, Anastasiou M, Pantazopoulos A, Kavourakis G, Gkolfinopoulos S, Panayiotides I, Delides A, Psyrri A. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol 2020;111:105013. [PMID: 32977184 DOI: 10.1016/j.oraloncology.2020.105013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
188 Hu W, Wang G, Wang Y, Riese MJ, You M. Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. iScience 2020;23:101580. [PMID: 33083746 DOI: 10.1016/j.isci.2020.101580] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
189 Zengin ZB, Salgia NJ, Chehrazi-Raffle A, Meza L, Malhotra J, Pal SK. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. Cancer J 2020;26:432-40. [PMID: 32947311 DOI: 10.1097/PPO.0000000000000473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
190 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
191 Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, Sullivan I, Barba A, Del Carpio L, Barnadas A, Gich I, Majem M. Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Front Oncol 2020;10:1677. [PMID: 33014837 DOI: 10.3389/fonc.2020.01677] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
192 Frelau A, Palard-Novello X, Jali E, Boussemart L, Dupuy A, James P, Devillers A, Le Jeune F, Edeline J, Lesimple T, Girard A. Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunol Immunother 2021;70:679-87. [PMID: 32880684 DOI: 10.1007/s00262-020-02712-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
193 Yokohama K, Asai A, Matsui M, Okamoto N, Yasuoka H, Nishikawa T, Ohama H, Tsuchimoto Y, Inoue Y, Fukunishi S, Uchiyama K, Higuchi K. Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Sci Rep 2020;10:14470. [PMID: 32879383 DOI: 10.1038/s41598-020-71561-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
194 Sakamoto K, Fukihara J, Morise M, Hashimoto N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respiratory Investigation 2020;58:305-19. [DOI: 10.1016/j.resinv.2020.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
195 Wei Q, Yuan X, Li J, Xu Q, Ying J. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study. Transl Cancer Res 2020;9:5315-22. [PMID: 35117897 DOI: 10.21037/tcr-20-1333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clin Infect Dis 2019;69:909-20. [PMID: 30520987 DOI: 10.1093/cid/ciy1025] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
197 Theiler-schwetz V, Trummer C, Richtig E, Richtig G, Pilz S. Schilddrüsenfunktionsstörungen unter Immuncheckpoint-Inhibitor-Therapie. J Klin Endokrinol Stoffw 2020;13:115-118. [DOI: 10.1007/s41969-020-00111-y] [Reference Citation Analysis]
198 Cooksley T, Girotra M, Ginex P, Gordon RA, Anderson R, Blidner A, Choi J, Dougan M, Glezerman I, Gupta D, Johnson D, Shannon VR, Suarez-almazor M, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Support Care Cancer 2020;28:6175-81. [DOI: 10.1007/s00520-020-05709-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
199 Yamada H, Okajima F, Onda T, Fujimori S, Emoto N, Sugihara H. New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report. BMC Endocr Disord 2020;20:132. [PMID: 32847555 DOI: 10.1186/s12902-020-00613-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
200 Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci 2021;64:512-33. [PMID: 32926318 DOI: 10.1007/s11427-020-1768-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
201 Takayama T, Murakami K, Minemura C, Yoshidome R, Yamamura K, Yokoe H. A case of simultaneous double cancer of oral malignant melanoma and lung adenocarcinoma with nivolumab-induced destructive thyroiditis. Jpn J Oral Maxillofac Surg 2020;66:376-381. [DOI: 10.5794/jjoms.66.376] [Reference Citation Analysis]
202 Albrethsen M, Creeden J, Morand S, DeBiase J, Berry B, Stanbery L, Edelman G, Nemunaitis J. Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. Immunotherapy 2020;12:1041-6. [PMID: 32808556 DOI: 10.2217/imt-2020-0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
203 Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. Cancers (Basel) 2020;12:E2314. [PMID: 32824462 DOI: 10.3390/cancers12082314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
204 Gu Y, Zhang H, Liu Z, Xia Y, Liang B, Liang L. Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. Asia Pac J Clin Oncol 2020;16:e160-78. [PMID: 32779383 DOI: 10.1111/ajco.13385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
205 Qin Q, Wang J, Wang H. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review]. Zhongguo Fei Ai Za Zhi 2020;23:772-91. [PMID: 32752580 DOI: 10.3779/j.issn.1009-3419.2020.104.07] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
206 Richter MD, Hughes GC, Chung SH, Ezeanuna M, Singh N, Thompson JA. Immunologic adverse events from immune checkpoint therapy. Best Practice & Research Clinical Rheumatology 2020;34:101511. [DOI: 10.1016/j.berh.2020.101511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
207 Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 2020;85:106628. [DOI: 10.1016/j.intimp.2020.106628] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
208 Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol 2020;13:105. [PMID: 32723363 DOI: 10.1186/s13045-020-00940-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
209 Li H, Zhou X, Zhang D, Wang G, Cheng X, Xu C, Yao B, Pang L, Chen J. Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature. Front Med (Lausanne) 2020;7:366. [PMID: 32850889 DOI: 10.3389/fmed.2020.00366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
210 Lima Ferreira J, Costa C, Marques B, Castro S, Victor M, Oliveira J, Santos AP, Sampaio IL, Duarte H, Marques AP, Torres I. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother 2021;70:299-309. [DOI: 10.1007/s00262-020-02664-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
211 Latteyer S, Christoph S, Theurer S, Hönes GS, Schmid KW, Führer D, Moeller LC. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr Relat Cancer 2019;26:565-74. [PMID: 30893642 DOI: 10.1530/ERC-18-0353] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
212 Pollack R, Ashash A, Cahn A, Rottenberg Y, Stern H, Dresner-pollak R. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index. The Journal of Clinical Endocrinology & Metabolism 2020;105:e3620-7. [DOI: 10.1210/clinem/dgaa458] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
213 Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clin Genitourin Cancer 2021;19:208-216.e1. [PMID: 32800718 DOI: 10.1016/j.clgc.2020.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
214 Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 2019;26:G1-G18. [PMID: 30400055 DOI: 10.1530/ERC-18-0320] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 22.3] [Reference Citation Analysis]
215 Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bull Cancer 2020;107:946-58. [PMID: 32646604 DOI: 10.1016/j.bulcan.2020.04.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
216 Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab 2019;14:381-98. [PMID: 31842671 DOI: 10.1080/17446651.2019.1701434] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
217 Zhao JJ, Wen XZ, Ding Y, Li DD, Zhu BY, Li JJ, Weng DS, Zhang X, Zhang XS. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. Aging (Albany NY) 2020;12:10663-75. [PMID: 32516130 DOI: 10.18632/aging.103285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
218 Citarella F, Russano M, Pantano F, Dell'Aquila E, Vincenzi B, Tonini G, Santini D. Facing SARS-CoV-2 outbreak in immunotherapy era. Future Oncol 2020;16:1475-85. [PMID: 32468851 DOI: 10.2217/fon-2020-0340] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
219 Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, Gandhi M, Ryder M. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations. Thyroid 2020;30:1440-50. [PMID: 32323619 DOI: 10.1089/thy.2020.0075] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
220 Fuentes-Antrás J, Peinado P, Guevara-Hoyer K, Del Arco CD, Sánchez-Ramón S, Aguado C. Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30098-4. [PMID: 32442551 DOI: 10.1016/j.hemonc.2020.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
221 Abdou Y, Pandey M, Sarma M, Shah S, Baron J, Ernstoff MS. Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. Br J Clin Pharmacol 2020;86:1690-702. [PMID: 32323342 DOI: 10.1111/bcp.14316] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
222 Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid 2020;30:1458-69. [PMID: 32264785 DOI: 10.1089/thy.2020.0032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
223 Isoda A, Miyazawa Y, Tahara K, Mihara M, Saito A, Matsumoto M, Sawamura M. Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin. Intern Med 2020;59:2041-5. [PMID: 32389947 DOI: 10.2169/internalmedicine.4467-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
224 Parthymos I, Liamis G, Dounousi E, Pentheroudakis G, Mauri D, Zarkavelis G, Florentin M. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. Crit Rev Oncol Hematol 2020;151:102979. [PMID: 32480349 DOI: 10.1016/j.critrevonc.2020.102979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
225 Music M, Iafolla M, Soosaipillai A, Batruch I, Prassas I, Pintilie M, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Siu LL, Diamandis EP. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. F1000Res 2020;9:337. [PMID: 33299547 DOI: 10.12688/f1000research.22715.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
226 Lorch JH. Development of Overt Thyroid Dysfunction and Antithyroid Antibodies with Anti-PD-1 Use in Various Cancers Is Associated with Favorable Survival. Clinical Thyroidology 2020;32:221-4. [DOI: 10.1089/ct.2020;32.221-224] [Reference Citation Analysis]
227 Deligiorgi MV, Panayiotidis MI, Trafalis DT. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy 2020;12:481-510. [PMID: 32345074 DOI: 10.2217/imt-2019-0132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
228 Basak EA, van der Meer JWM, Hurkmans DP, Schreurs MWJ, Oomen-de Hoop E, van der Veldt AAM, Bins S, Joosse A, Koolen SLW, Debets R, Peeters RP, Aerts JGJV, Mathijssen RHJ, Medici M. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Thyroid 2020;30:966-73. [PMID: 32151195 DOI: 10.1089/thy.2019.0726] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
229 Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 2020;18:87. [PMID: 32306958 DOI: 10.1186/s12916-020-01549-2] [Cited by in Crossref: 96] [Cited by in F6Publishing: 103] [Article Influence: 32.0] [Reference Citation Analysis]
230 Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol 2019;20:e54-64. [PMID: 30614479 DOI: 10.1016/S1470-2045(18)30828-3] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 31.7] [Reference Citation Analysis]
231 Vani V, Regge D, Cappello G, Gabelloni M, Neri E. Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. Diagnostics (Basel) 2020;10:E216. [PMID: 32294888 DOI: 10.3390/diagnostics10040216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
232 Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.Rheumatology (Oxford). 2019;58:vii59-vii67. [PMID: 31816080 DOI: 10.1093/rheumatology/kez308] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 27.0] [Reference Citation Analysis]
233 Chen VE, Greenberger BA, Taylor JM, Edelman MJ, Lu B. The Underappreciated Role of the Humoral Immune System and B Cells in Tumorigenesis and Cancer Therapeutics: A Review. Int J Radiat Oncol Biol Phys 2020;108:38-45. [PMID: 32251756 DOI: 10.1016/j.ijrobp.2020.03.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
234 Hayakawa N, Kikuchi E, Suzuki S, Oya M. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma. Int Cancer Conf J 2020;9:123-6. [PMID: 32582515 DOI: 10.1007/s13691-020-00408-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
235 Khan S, von Itzstein MS, Lu R, Bermas BL, Karp DR, Khan SA, Fattah FJ, Park JY, Saltarski JM, Gloria-McCutchen Y, Xie Y, Li QZ, Wakeland EK, Gerber DE. Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon. Oncologist 2020;25:e753-7. [PMID: 32167195 DOI: 10.1634/theoncologist.2019-0666] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
236 Yang H, Yao Z, Zhou X, Zhang W, Zhang X, Zhang F. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clin Immunol 2020;213:108377. [PMID: 32135278 DOI: 10.1016/j.clim.2020.108377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
237 Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol 2020;200:131-40. [PMID: 32027018 DOI: 10.1111/cei.13424] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 18.7] [Reference Citation Analysis]
238 Li Y, Li CQ, Guo SJ, Guo W, Jiang HW, Li HC, Tao SC. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma. EBioMedicine 2020;53:102674. [PMID: 32113159 DOI: 10.1016/j.ebiom.2020.102674] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
239 Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, Hisakane K, Takahashi S, Tanaka T, Takeuchi S, Miyanaga A, Minegishi Y, Noro R, Kubota K, Gemma A. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 2020;11:1052-60. [PMID: 32096610 DOI: 10.1111/1759-7714.13364] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
240 Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, Mcdonald L, Karagiannis SN, Taams LS, Powell N, Cope A, Papa S. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol 2020;200:141-54. [PMID: 31989585 DOI: 10.1111/cei.13421] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
241 Kim KH, Kim CG, Shin EC. Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Netw 2020;20:e8. [PMID: 32158596 DOI: 10.4110/in.2020.20.e8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
242 Bhattacharya S, Goyal A, Kaur P, Singh R, Kalra S. Anticancer Drug-induced Thyroid Dysfunction. Eur Endocrinol 2020;16:32-9. [PMID: 32595767 DOI: 10.17925/EE.2020.16.1.32] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
243 Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 2020;9:1722023. [PMID: 32076579 DOI: 10.1080/2162402X.2020.1722023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
244 Cugnet Anceau C, Abeillon J, Maillet D, Borson-chazot F, Disse E. Les dysthyroïdies sous immunothérapie anti-cancéreuse. Bulletin du Cancer 2020;107:262-71. [DOI: 10.1016/j.bulcan.2019.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
245 España S, Pérez Montes de Oca A, Marques-Pamies M, Cucurull M, Domenech M, Velarde JM, Salinas I, Moran T, Etxaniz O. Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution. Transl Lung Cancer Res 2020;9:103-10. [PMID: 32206558 DOI: 10.21037/tlcr.2019.12.17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
246 Angell TE. Thyroiditis While Receiving Programmed Death Ligand 1 (PD-L1) Inhibitor Therapy for Nonthyroid Cancers Is Associated with Improved Overall Survival. Clinical Thyroidology 2020;32:65-8. [DOI: 10.1089/ct.2020;32.65-68] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
247 Wang X, Wu S, Chen Y, Shao E, Zhuang T, Lu L, Chen X. Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:5. [PMID: 32076409 DOI: 10.3389/fphar.2020.00005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
248 Helmink BA, Roland CL, Kiernan CM, Wargo JA. Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. Ann Surg Oncol 2020;27:1533-45. [PMID: 31965370 DOI: 10.1245/s10434-019-08183-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
249 Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin 2020;70:86-104. [PMID: 31944278 DOI: 10.3322/caac.21596] [Cited by in Crossref: 364] [Cited by in F6Publishing: 398] [Article Influence: 121.3] [Reference Citation Analysis]
250 Agrawal L, Bacal A, Jain S, Singh V, Emanuele N, Emanuele M, Meah F. Immune checkpoint inhibitors and endocrine side effects, a narrative review. Postgrad Med 2020;132:206-14. [PMID: 31876444 DOI: 10.1080/00325481.2019.1709344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
251 Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid 2020;30:177-84. [PMID: 31813343 DOI: 10.1089/thy.2019.0250] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 22.7] [Reference Citation Analysis]
252 Marin-Acevedo JA, Chirila RM, Dronca RS. Immune Checkpoint Inhibitor Toxicities. Mayo Clin Proc 2019;94:1321-9. [PMID: 31272574 DOI: 10.1016/j.mayocp.2019.03.012] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 20.0] [Reference Citation Analysis]
253 Zaborowski M, Sywak M, Nylén C, Gill AJ, Chou A. Unique and distinctive histological features of immunotherapy-related thyroiditis. Pathology 2020;52:271-3. [PMID: 31902621 DOI: 10.1016/j.pathol.2019.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
254 Connolly JG, Bott MJ, Jones DR. Does Induction Immunotherapy Confer Increased Operative Risk for Lung Resection? Difficult Decisions in Surgery: An Evidence-Based Approach 2020. [DOI: 10.1007/978-3-030-47404-1_17] [Reference Citation Analysis]
255 Su Z, Zhou L, Xue J, Lu Y. Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. Chin J Cancer Res 2020;32:448-66. [PMID: 32963458 DOI: 10.21147/j.issn.1000-9604.2020.04.03] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
256 Percik R, Shoenfeld Y. Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to? Best Practice & Research Clinical Endocrinology & Metabolism 2020;34:101411. [DOI: 10.1016/j.beem.2020.101411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
257 Sbardella E, Tenuta M, Sirgiovanni G, Gianfrilli D, Pozza C, Venneri MA, Cortesi E, Marchetti P, Lenzi A, Gelibter AJ, Isidori AM. Thyroid disorders in programmed death 1 inhibitor‐treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor? Clin Endocrinol 2020;92:258-65. [DOI: 10.1111/cen.14135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
258 Pandey M, Goyal I, Ernstoff MS. Endocrine Toxicities of Immunotherapy. Handbook of Cancer Treatment-Related Symptons and Toxicities 2020. [DOI: 10.1016/b978-0-323-67241-2.00018-5] [Reference Citation Analysis]
259 Patil PD, Velcheti V. Mechanisms of Immune-Related Adverse Events. Handbook of Cancer Treatment-Related Symptons and Toxicities 2020. [DOI: 10.1016/b978-0-323-67241-2.00017-3] [Reference Citation Analysis]
260 Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer 2020;140:59-64. [PMID: 31881412 DOI: 10.1016/j.lungcan.2019.12.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
261 Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2019;5:376-83. [PMID: 30589930 DOI: 10.1001/jamaoncol.2018.5860] [Cited by in Crossref: 139] [Cited by in F6Publishing: 154] [Article Influence: 34.8] [Reference Citation Analysis]
262 Rajha E, Chaftari P, Kamal M, Maamari J, Chaftari C, Yeung SJ. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol Rep (Oxf) 2020;8:25-30. [PMID: 32104583 DOI: 10.1093/gastro/goz065] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
263 Percik R, Shlomai G, Tirosh A, Tirosh A, Leibowitz-Amit R, Eshet Y, Greenberg G, Merlinsky A, Barhod E, Steinberg-Silman Y, Sella T. Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmun Rev 2020;19:102454. [PMID: 31838158 DOI: 10.1016/j.autrev.2019.102454] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
264 Ville S, Kandel-Aznar C, Frémeaux-Bacchi V, Fakhouri F. C3 glomerulonephritis in a patient treated with anti-PD-1 antibody. Eur J Cancer 2020;125:46-8. [PMID: 31838404 DOI: 10.1016/j.ejca.2019.11.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
265 Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S, Guo Y, Cai S, Wang Y, Li J. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 2019;7:341. [PMID: 31801636 DOI: 10.1186/s40425-019-0779-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 20.5] [Reference Citation Analysis]
266 Li Y, Wang Z, Guo T, Liu S, Feng C. Treatment-related adverse events and response rate to immune checkpoint inhibition. J Int Med Res 2020;48:300060519886454. [PMID: 31777292 DOI: 10.1177/0300060519886454] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
267 Labadie BW, Liu P, Bao R, Crist M, Fernandes R, Ferreira L, Graupner S, Poklepovic AS, Duran I, Maleki Vareki S, Balar AV, Luke JJ. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. J Transl Med 2019;17:386. [PMID: 31767020 DOI: 10.1186/s12967-019-02144-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
268 Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, Alexander JL, Pinato DJ. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology 2020;159:167-77. [PMID: 31646612 DOI: 10.1111/imm.13141] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 12.0] [Reference Citation Analysis]
269 Hou J, Xiong SS, Huang ZQ, Cai XD. Decelerated tumor growth due to hypothyroidism with prolongation of survival in a patient with lung adenocarcinoma: a case report. J Int Med Res 2020;48:300060519885302. [PMID: 31736387 DOI: 10.1177/0300060519885302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
270 Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R, Ogasawara T, Tsurumi K, Ono K, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. Oncologist 2020;25:e536-44. [PMID: 32162801 DOI: 10.1634/theoncologist.2019-0550] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
271 Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J. Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev 2019;28:190012. [PMID: 31694838 DOI: 10.1183/16000617.0012-2019] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
272 Dupont R, Bérard E, Puisset F, Comont T, Delord JP, Guimbaud R, Meyer N, Mazieres J, Alric L. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. Oncoimmunology 2020;9:1682383. [PMID: 32002292 DOI: 10.1080/2162402X.2019.1682383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
273 Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Clinical Lung Cancer 2019;20:442-450.e4. [DOI: 10.1016/j.cllc.2019.07.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
274 Esfahani K, Meti N, Miller WH, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019;191:E40-E46. [PMID: 30642824 DOI: 10.1503/cmaj.180870] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
275 Del Rivero J, Cordes LM, Klubo-Gwiezdzinska J, Madan RA, Nieman LK, Gulley JL. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. Oncologist. 2020;25:290-300. [PMID: 32297436 DOI: 10.1634/theoncologist.2018-0470] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
276 Liu YH, Zang XY, Wang JC, Huang SS, Xu J, Zhang P. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomed Pharmacother 2019;120:109437. [PMID: 31590992 DOI: 10.1016/j.biopha.2019.109437] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
277 Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z, Wang X. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Front Immunol 2019;10:2298. [PMID: 31636634 DOI: 10.3389/fimmu.2019.02298] [Cited by in Crossref: 153] [Cited by in F6Publishing: 166] [Article Influence: 38.3] [Reference Citation Analysis]
278 Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol 2020;22:919-27. [PMID: 31576495 DOI: 10.1007/s12094-019-02214-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
279 Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, Tomasello G, Barni S, Berruti A, Brighenti M. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy 2020;43:1-7. [DOI: 10.1097/cji.0000000000000300] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
280 Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res 2018;6:1445-52. [PMID: 30510057 DOI: 10.1158/2326-6066.CIR-18-0487] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 22.5] [Reference Citation Analysis]
281 Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol 2018;4:374-8. [PMID: 28975219 DOI: 10.1001/jamaoncol.2017.2925] [Cited by in Crossref: 531] [Cited by in F6Publishing: 574] [Article Influence: 132.8] [Reference Citation Analysis]
282 Zdanyte K, Kiesel L. Onkologische Immuntherapie und mögliche endokrine Nebenwirkungen bei Frauen. Gynäkologische Endokrinologie 2019;17:185-188. [DOI: 10.1007/s10304-019-0255-x] [Reference Citation Analysis]
283 Galli G, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. Tumori Journal 2019;105:NP57-62. [DOI: 10.1177/0300891619872546] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
284 Yamagata S, Kageyama K, Takayasu S, Asari Y, Makita K, Terui K, Daimon M. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. Intern Med 2019;58:3557-62. [PMID: 31462588 DOI: 10.2169/internalmedicine.3008-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
285 Queirolo P, Boutros A, Tanda E, Spagnolo F, Quaglino P. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. Semin Cancer Biol 2019;59:290-7. [PMID: 31430555 DOI: 10.1016/j.semcancer.2019.08.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 13.8] [Reference Citation Analysis]
286 Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Seminars in Oncology 2019;46:362-71. [DOI: 10.1053/j.seminoncol.2019.10.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
287 Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, Al-Rohil RN, Mobley BC, Salem JE, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem JM, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger SM, Rushing EJ, Buchbinder EI, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 2019;25:1243-50. [PMID: 31332390 DOI: 10.1038/s41591-019-0523-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 24.3] [Reference Citation Analysis]
288 Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin Cancer Biol 2020;64:93-101. [PMID: 31330185 DOI: 10.1016/j.semcancer.2019.06.012] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 16.5] [Reference Citation Analysis]
289 Brancatella A, Viola N, Brogioni S, Montanelli L, Sardella C, Vitti P, Marcocci C, Lupi I, Latrofa F. Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature. Eur Thyroid J 2019;8:192-5. [PMID: 31602361 DOI: 10.1159/000501824] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
290 Kennedy LB, Salama AKS. A Review of Immune-Mediated Adverse Events in Melanoma. Oncol Ther 2019;7:101-20. [PMID: 32699983 DOI: 10.1007/s40487-019-0096-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
291 Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer 2019;20:237-247.e1. [DOI: 10.1016/j.cllc.2019.02.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 19.0] [Reference Citation Analysis]
292 Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf 2019;42:281-94. [PMID: 30649742 DOI: 10.1007/s40264-018-0774-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
293 Gokozan HN, Friedman JD, Schmaier AH, Downes KA, Farah LA, Reeves HM. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab. Clin Lung Cancer 2019;20:e560-3. [PMID: 31311716 DOI: 10.1016/j.cllc.2019.06.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
294 Miura S, Isogai S, Yoshino M, Baba J, Kajiwara T, Koyama K, Takenouchi T, Tani N, Tanaka H. Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. JJLC 2019;59:231-237. [DOI: 10.2482/haigan.59.231] [Reference Citation Analysis]
295 Zhang X, Wu Y, Lv J, Li X, Ma L, Nong J, Zhang H, Qin N, Zhang Q, Shi G, Yang X, Wang J, Zhang S. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer. Interdiscip Sci 2019;11:287-91. [PMID: 31187431 DOI: 10.1007/s12539-019-00337-8] [Reference Citation Analysis]
296 Sakakida T, Ishikawa T, Uchino J, Chihara Y, Komori S, Asai J, Narukawa T, Arai A, Kobayashi T, Tsunezuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. Oncol Lett 2019;18:2140-7. [PMID: 31423288 DOI: 10.3892/ol.2019.10466] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
297 Sibille A, Alfieri R, Malaise O, Detrembleur N, Pirotte M, Louis R, Duysinx B. Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer. Front Oncol 2019;9:478. [PMID: 31245290 DOI: 10.3389/fonc.2019.00478] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
298 Dhenin A, Samartzi V, Lejeune S, Seront E. Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ Case Rep. 2019;12. [PMID: 31167767 DOI: 10.1136/bcr-2018-229149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
299 Jannin A, Penel N, Ladsous M, Vantyghem MC, Do Cao C. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit Rev Oncol Hematol. 2019;141:23-35. [PMID: 31202955 DOI: 10.1016/j.critrevonc.2019.05.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
300 Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Patrizio A, Galdiero MR, Baldini E, Ulisse S, Marone G, Antonelli A. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int J Mol Sci 2019;20:E2560. [PMID: 31137683 DOI: 10.3390/ijms20102560] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
301 Ksienski D, Wai ES, Croteau N, Freeman AT, Chan A, Fiorino L, Brooks EG, Poonja Z, Fenton D, Geller G, Irons S, Lesperance M. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice. Lung Cancer 2019;133:110-6. [PMID: 31200816 DOI: 10.1016/j.lungcan.2019.05.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
302 Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev. 2019;40:17-65. [PMID: 30184160 DOI: 10.1210/er.2018-00006] [Cited by in Crossref: 218] [Cited by in F6Publishing: 235] [Article Influence: 54.5] [Reference Citation Analysis]
303 Mazarico I, Capel I, Giménez-Palop O, Albert L, Berges I, Luchtenberg F, García Y, Fernández-Morales LA, De Pedro VJ, Caixàs A, Rigla M. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. J Endocrinol Invest 2019;42:1443-50. [PMID: 31093955 DOI: 10.1007/s40618-019-01058-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
304 Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 2019;14:e0216954. [PMID: 31086392 DOI: 10.1371/journal.pone.0216954] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
305 Koyama J, Horiike A, Yoshizawa T, Dotsu Y, Ariyasu R, Saiki M, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ninomiya H, Ishikawa Y, Nishio M. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. J Thorac Dis 2019;11:1919-28. [PMID: 31285885 DOI: 10.21037/jtd.2019.04.102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
306 Remon J, Reguart N, Auclin E, Besse B. Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy? J Thorac Oncol 2019;14:963-7. [PMID: 31027971 DOI: 10.1016/j.jtho.2019.02.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
307 Campredon P, Mouly C, Lusque A, Bigay-Game L, Bousquet E, Mazières J, Caron P. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. Presse Med 2019;48:e199-207. [PMID: 31005502 DOI: 10.1016/j.lpm.2018.10.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
308 Ladak K, Bass AR. Checkpoint inhibitor-associated autoimmunity. Best Pract Res Clin Rheumatol 2018;32:781-802. [PMID: 31427055 DOI: 10.1016/j.berh.2019.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
309 Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord 2018;19:325-33. [PMID: 30242549 DOI: 10.1007/s11154-018-9463-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 13.8] [Reference Citation Analysis]
310 Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. Clin Drug Investig 2019;39:319-30. [PMID: 30674039 DOI: 10.1007/s40261-018-0735-0] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
311 Sanchez K, Page DB, Urba W. Immunotherapy Toxicities. Surg Oncol Clin N Am 2019;28:387-401. [PMID: 31079795 DOI: 10.1016/j.soc.2019.02.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
312 Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 2019;7:99. [PMID: 30944023 DOI: 10.1186/s40425-019-0579-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 19.8] [Reference Citation Analysis]
313 Ishihara H, Takagi T, Kondo T, Homma C, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 2019;37:355.e21-9. [PMID: 30935847 DOI: 10.1016/j.urolonc.2019.03.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
314 Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, Kim HR. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol 2019;145:1613-23. [PMID: 30911841 DOI: 10.1007/s00432-019-02899-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
315 Fujita Y, Tinoco R, Li Y, Senft D, Ronai ZA. Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity. Trends Mol Med 2019;25:428-43. [PMID: 30898473 DOI: 10.1016/j.molmed.2019.02.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
316 Okawa S, Kayatani H, Fujiwara K, Ozeki T, Takada K, Iwamoto Y, Minami D, Sato K, Shibayama T. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med 2019;58:699-702. [PMID: 30828042 DOI: 10.2169/internalmedicine.1001-18] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
317 Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 2019;7:57. [PMID: 30813970 DOI: 10.1186/s40425-019-0527-y] [Cited by in Crossref: 176] [Cited by in F6Publishing: 185] [Article Influence: 44.0] [Reference Citation Analysis]
318 Peiró I, Palmero R, Iglesias P, Díez JJ, Simó-Servat A, Marín JA, Jiménez L, Domingo-Domenech E, Mancho-Fora N, Nadal E, Villabona C. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 2019;64:605-13. [PMID: 30805887 DOI: 10.1007/s12020-019-01871-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
319 Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. Front Endocrinol (Lausanne) 2019;10:59. [PMID: 30814976 DOI: 10.3389/fendo.2019.00059] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 19.5] [Reference Citation Analysis]
320 Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 2019;68:341-52. [PMID: 30725206 DOI: 10.1007/s00262-019-02310-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
321 Scarpelli M, Zahm C, Perlman S, McNeel DG, Jeraj R, Liu G. FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer 2019;7:23. [PMID: 30700328 DOI: 10.1186/s40425-019-0516-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
322 Tan MH, Iyengar R, Mizokami-Stout K, Yentz S, MacEachern MP, Shen LY, Redman B, Gianchandani R. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1. [PMID: 30693099 DOI: 10.1186/s40842-018-0073-4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 19.3] [Reference Citation Analysis]
323 Iadarola C, Croce L, Quaquarini E, Teragni C, Pinto S, Bernardo A, Fonte R, Marinò M, Rotondi M, Chiovato L. Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis. Front Endocrinol (Lausanne) 2018;9:813. [PMID: 30705667 DOI: 10.3389/fendo.2018.00813] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
324 Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, Fenton D, Geller G, Glick D, Lesperance M. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Clinical Lung Cancer 2019;20:e97-e106. [DOI: 10.1016/j.cllc.2018.09.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
325 Naidoo J, Dykema A, D'Alessio F. An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. J Clin Invest 2019;129:75-7. [PMID: 30530990 DOI: 10.1172/JCI125800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
326 Nakamura K, Okubo K, Takahashi T, Mitsumori K, Ishigaki T, Ohnishi H. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma. IJU Case Rep 2019;2:30-3. [PMID: 32743367 DOI: 10.1002/iju5.12032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
327 Garon-Czmil J, Petitpain N, Rouby F, Sassier M, Babai S, Yelehe-Okouma M, Weryha G, Klein M, Gillet P. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database. Fundam Clin Pharmacol 2019;33:241-9. [PMID: 30308083 DOI: 10.1111/fcp.12423] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
328 Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor: Association between soluble immune mediators and tumor responses. Int J Cancer 2019;144:1170-9. [DOI: 10.1002/ijc.31923] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
329 Zimmermann S, Peters S, Owinokoko T, Gadgeel SM. Immune Checkpoint Inhibitors in the Management of Lung Cancer. Am Soc Clin Oncol Educ Book 2018;38:682-95. [PMID: 30231367 DOI: 10.1200/EDBK_201319] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
330 Spagnuolo A, Gridelli C. "Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not? J Thorac Dis 2018;10:S4065-8. [PMID: 30631556 DOI: 10.21037/jtd.2018.09.83] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
331 Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, Lu R, Xie Y, Li Q, Wakeland E, Gerber DE. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer 2019;120:63-8. [PMID: 30377338 DOI: 10.1038/s41416-018-0155-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 14.6] [Reference Citation Analysis]
332 Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 2018;109:3583-90. [PMID: 30230649 DOI: 10.1111/cas.13800] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
333 Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Clin Lung Cancer. 2019;20:201-207. [PMID: 30442524 DOI: 10.1016/j.cllc.2018.10.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 16.0] [Reference Citation Analysis]
334 Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment]. Bull Cancer 2018;105:1033-41. [PMID: 30244981 DOI: 10.1016/j.bulcan.2018.07.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
335 Delaunay M, Caron P, Sibaud V, Godillot C, Collot S, Milia J, Prévot G, Mazières J. [Toxicity of immune checkpoints inhibitors]. Rev Mal Respir 2018;35:1028-38. [PMID: 30213624 DOI: 10.1016/j.rmr.2017.08.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
336 Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, Shields PG, Carbone DP, Otterson GA. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Clin Lung Cancer 2018;19:e893-900. [PMID: 30197259 DOI: 10.1016/j.cllc.2018.08.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 12.4] [Reference Citation Analysis]
337 Lauko A, Thapa B, Venur VA, Ahluwalia MS. Management of Brain Metastases in the New Era of Checkpoint Inhibition. Curr Neurol Neurosci Rep 2018;18:70. [PMID: 30121715 DOI: 10.1007/s11910-018-0877-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
338 Wills B, Brahmer JR, Naidoo J. Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. Curr Treat Options Oncol 2018;19:46. [PMID: 30101402 DOI: 10.1007/s11864-018-0562-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
339 Palmieri DJ, Carlino MS. Immune Checkpoint Inhibitor Toxicity. Curr Oncol Rep 2018;20. [DOI: 10.1007/s11912-018-0718-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
340 Illouz F, Drui D, Caron P, Do Cao C. Expert opinion on thyroid complications in immunotherapy. Ann Endocrinol (Paris) 2018;79:555-61. [PMID: 30126627 DOI: 10.1016/j.ando.2018.07.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
341 Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectr 2018;2:pky021. [PMID: 30057972 DOI: 10.1093/jncics/pky021] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 14.0] [Reference Citation Analysis]
342 Sury K, Perazella MA, Shirali AC. Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 2018;14:571-88. [DOI: 10.1038/s41581-018-0035-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 57] [Article Influence: 10.2] [Reference Citation Analysis]
343 Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142. [PMID: 28881921 DOI: 10.1093/annonc/mdx225] [Cited by in Crossref: 1191] [Cited by in F6Publishing: 1261] [Article Influence: 238.2] [Reference Citation Analysis]
344 Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H, Kodama K, Emoto M. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC. Cancer Immunol Immunother 2018;67:1417-24. [PMID: 29995236 DOI: 10.1007/s00262-018-2203-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
345 Rossi S, Castello A, Toschi L, Lopci E. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy 2018;10:797-805. [DOI: 10.2217/imt-2017-0187] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
346 Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. Oncologist 2018;23:1358-65. [PMID: 29934411 DOI: 10.1634/theoncologist.2017-0384] [Cited by in Crossref: 136] [Cited by in F6Publishing: 148] [Article Influence: 27.2] [Reference Citation Analysis]
347 Temel JS, Gainor JF, Sullivan RJ, Greer JA. Keeping Expectations in Check With Immune Checkpoint Inhibitors. JCO 2018;36:1654-7. [DOI: 10.1200/jco.2017.76.2146] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
348 Bianco A, Malapelle U, Rocco D, Perrotta F, Mazzarella G. Targeting immune checkpoints in non small cell lung cancer. Current Opinion in Pharmacology 2018;40:46-50. [DOI: 10.1016/j.coph.2018.02.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
349 Hamada S, Fuseya Y, Tsukino M. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. Archivos de Bronconeumología (English Edition) 2018;54:346-8. [DOI: 10.1016/j.arbr.2018.01.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
350 Drouin S, Kuhn E. Comment l’urologue et son réseau de soin peuvent prendre en charge la toxicité des immunothérapies ? Application aux toxicités endocriniennes. Progrès en Urologie - FMC 2018;28:F47-F50. [DOI: 10.1016/j.fpurol.2018.05.003] [Reference Citation Analysis]
351 Hamada S, Fuseya Y, Tsukino M. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. Archivos de Bronconeumología 2018;54:346-8. [DOI: 10.1016/j.arbres.2018.01.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
352 Maekura T, Naito M, Tahara M, Ikegami N, Kimura Y, Sonobe S, Kobayashi T, Tsuji T, Minomo S, Tamiya A, Atagi S. Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer. In Vivo 2017;31:1035-9. [PMID: 28882978 DOI: 10.21873/invivo.11166] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
353 Weber JS. Challenging Cases: Management of Immune-Related Toxicity. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_209557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
354 Jaafar J, Fernandez E, Alwan H, Philippe J. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocr Connect 2018;7:R196-211. [PMID: 29739808 DOI: 10.1530/EC-18-0079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
355 Tay R, Prelaj A, Califano R. Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. J Thorac Dis 2018;10:S1494-502. [PMID: 29951301 DOI: 10.21037/jtd.2018.01.80] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
356 Remon J, Mezquita L, Corral J, Vilariño N, Reguart N. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis 2018;10:S1516-33. [PMID: 29951303 DOI: 10.21037/jtd.2017.12.52] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
357 Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. 18F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. J Nucl Med Technol 2018;46:260-4. [PMID: 29599403 DOI: 10.2967/jnmt.117.204933] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
358 Wilson R, Menassa DA, Davies AJ, Michael S, Hester J, Kuker W, Collins GP, Cossins J, Beeson D, Steven N, Maddison P, Rinaldi S, Jacob S, Irani SR. Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Ann Clin Transl Neurol 2018;5:640-5. [PMID: 29761126 DOI: 10.1002/acn3.547] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
359 Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS. Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. Ann Thorac Surg 2018;106:178-83. [PMID: 29550207 DOI: 10.1016/j.athoracsur.2018.02.030] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
360 Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer 2018;119:14-20. [PMID: 29656747 DOI: 10.1016/j.lungcan.2018.02.017] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 17.6] [Reference Citation Analysis]
361 Spaulding SW. Patients with Advanced Lung Cancer in Whom Thyroid Dysfunction Develops During Programmed Death-1 Protein Blockade May Have a Good Prognosis. Clinical Thyroidology 2018;30:132-4. [DOI: 10.1089/ct.2018;30.132-134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
362 Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. J Endocr Soc 2018;2:241-51. [PMID: 29600292 DOI: 10.1210/js.2017-00432] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 20.4] [Reference Citation Analysis]
363 Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 2018;128:715-20. [PMID: 29309048 DOI: 10.1172/JCI96798] [Cited by in Crossref: 206] [Cited by in F6Publishing: 216] [Article Influence: 41.2] [Reference Citation Analysis]
364 Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer 2018;124:1111-21. [PMID: 29313945 DOI: 10.1002/cncr.31200] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
365 Janning M, Loges S. Management immunvermittelter Nebenwirkungen. hautnah dermatologie 2018;34:38-48. [DOI: 10.1007/s15012-018-2606-z] [Reference Citation Analysis]
366 Antonelli A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid cancer. Expert Rev Anticancer Ther 2018;18:149-59. [PMID: 29241377 DOI: 10.1080/14737140.2018.1417845] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
367 Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P. Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest. 2018;41:625-638. [PMID: 29238906 DOI: 10.1007/s40618-017-0778-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
368 Norris DC. One-size-fits-all dosing in oncology wastes money, innovation and lives. Drug Discov Today 2018;23:4-6. [PMID: 29170137 DOI: 10.1016/j.drudis.2017.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
369 Kim HI, Kim M, Lee SH, Park SY, Kim YN, Kim H, Jeon MJ, Kim TY, Kim SW, Kim WB, Kim SW, Lee DH, Park K, Ahn MJ, Chung JH, Shong YK, Kim WG, Kim TH. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. Oncoimmunology. 2017;7:e1375642. [PMID: 29296533 DOI: 10.1080/2162402x.2017.1375642] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 9.5] [Reference Citation Analysis]
370 Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol 2017;12:1798-805. [PMID: 28939128 DOI: 10.1016/j.jtho.2017.08.022] [Cited by in Crossref: 238] [Cited by in F6Publishing: 260] [Article Influence: 39.7] [Reference Citation Analysis]
371 Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab 2017;102:2770-80. [PMID: 28609832 DOI: 10.1210/jc.2017-00448] [Cited by in Crossref: 127] [Cited by in F6Publishing: 140] [Article Influence: 21.2] [Reference Citation Analysis]
372 Janning M, Loges S. Management immunvermittelter Nebenwirkungen. Info Onkol 2017;20:54-64. [DOI: 10.1007/s15004-017-5562-6] [Reference Citation Analysis]
373 Lena H, Ricordel C. Les complications de l’immunothérapie. Revue des Maladies Respiratoires Actualités 2017;9:325-331. [DOI: 10.1016/s1877-1203(17)30064-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
374 Iglesias P. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. Eur J Intern Med 2018;47:6-13. [PMID: 28826822 DOI: 10.1016/j.ejim.2017.08.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
375 Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017;50:1700050. [PMID: 28798088 DOI: 10.1183/13993003.00050-2017] [Cited by in Crossref: 187] [Cited by in F6Publishing: 208] [Article Influence: 31.2] [Reference Citation Analysis]
376 Norris DC. Costing ‘the’ MTD.. [DOI: 10.1101/150821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
377 Yoshihara M, Kimura R, Kunii E, Mori Y, Horiuchi M, Akita K. Two Patients with Non-small Cell Lung Cancer Developed Thyroid Dysfunction Accompanied by the Emergence of Anti-thyroglobulin Antibodies During Nivolumab Therapy. Haigan 2017;57:308-14. [DOI: 10.2482/haigan.57.308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]